Prof. Stephan Stilgenbauer from University of Ulm, Germany, defines ultra high-risk CLL (chronic lymphocytic leukemia) and comments on its implications for patients. He outlines highlights from ASCO 2014 and EHA 2014 in CLL, addressing the latest data with ibrutinib from the RESONATE trial, and on resistance issues observed with ibrutinib. He also comments on the use of single vs. combination agents in CLL – including new treatments such as ibrutinib, idelalisib, and ABT199.
Keywords:
EMJ
Ultra high-risk CLL
Ibrutinib
Prof. Stephan Stilgenbauer
University of Ulm
Chronic Lymphocytic Leukemia (CLL)
ASCO 2014
EHA 2014
RESONATE trial
Ibrutinib
Idelalisib
ABT199
Advertisement